Pipeline news
-
24 September 2018
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from the ongoing ENCORE 601 cohort enrolling non-small cell lung cancer (NSCLC) patients previously treated with both chemotherapy and PD-(L)1 therapy.
-
24 September 2018
Epic Sciences, in partnership with Memorial Sloan Kettering (MSK), have demonstrated that a liquid biopsy blood test may be used in clinical trials to find patients who are likely to benefit from PSMA-targeted therapies, before treatment is initiated. The blood test, developed by Epic Sciences, looks on the surface of circulating tumor cells (CTCs) for a specific protein, called prostate-specific membrane antigen (PSMA), that is highly expressed in prostate cancer. In the study, the presence of PSMA-positive CTCs in patients with metastatic prostate cancer was related to the patient’s therapeutic response and clinical outcomes to an antibody drug conjugate (ADC) therapy targeting PSMA-positive prostate cancer cells.
-
Positive PEACHTREE Data to be Highlighted at EURETINA 2018
18 September 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Ron Neumann , MD, Uveitis Specialist at Maccabi Health Services , Tel Aviv, Israel and co-Chair of the International Symposium of Ocular Pharmacology and Therapeutics, during a Uveitis Free Paper session at the upcoming European Society of Retina Specialists (EURETINA) Congress 2018 in Vienna, Austria.
-
13 September 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Rahul N. Khurana , MD, an investigator for PEACHTREE, Partner at Northern California Retina Vitreous Associates , and Clinical Associate Professor in Ophthalmology at UCSF Medical Center , during a scientific session on Inflammation at the Retina Society 51st Annual Scientific Meeting in San Francisco , California.
-
Epic Sciences Announces Completion of $52 Million Series E Financing
12 September 2018
Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR). Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing.
-
Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery
12 September 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Viral Kansara, Ph.D. to the position of Vice President, Discovery.
-
11 September 2018
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Leslie Zacks as General Counsel and Chief Compliance Officer.
-
Researchers provide compelling evidence for multiple STI-detecting device
11 September 2018
Using mathematical modelling, researchers within the Applied Diagnostics Research and Evaluation Unit at the university concluded that a bespoke point-of care diagnostic device could significantly reduce the number of return clinical visits and the average time-to-cure from about a week to one day. The device is in early phases of development by Atlas Genetics Limited, following a grant from from Innovate UK via the Small Business Research Initiative.
-
06 September 2018
Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Lester Rodríguez as Vice President, Quality.
-
Marinus Appoints Scott Braunstein, MD to its Board of Directors
05 September 2018
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Dr. Scott Braunstein to its Board of Directors. Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points.
